Treatment of newly diagnosed myeloma

Leukemia

Volumn 23, Issue 3, 2009, Pages 449-456

  Palumbo, A ^a   Rajkumar, S V ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; STEROID; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE DISEASE; BONE NECROSIS; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHROMOSOME 13; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CLINICAL PROTOCOL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENE DELETION; HERPES ZOSTER; HUMAN; INFECTION; JAW DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

EID: 62549132481     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.325     Document Type: Review

References (53)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351 1860-1873.
2. Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc 2005; 80: 1371-1382.
3. Ries LAG, Eisner MP, Kosary CL, Linet M, Tamra T, Young JL et al. (eds). SEER cancer statistics review, 1975-2000. National Cancer Institute. Available at: http//seer.cancer.gov//csr/1975_2001. Accessed on 7 September 2004.
4. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590.
5. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Br J Haematol 2008; 141: 205-211.
6. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380-386.
7. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW et al Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87 1166-1172.
8. Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 tax transgenic mice and tax tumor transplants. Blood 2004; 104: 802-809.
9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
10. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
11. Van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
12. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379-398.
13. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
14. Gertz MA, Lacy MQ, Dispensieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
15. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
16. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489-3495.
17. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
18. Bahlis NJ, Song K, Trieu Y, Roland B, Masih-Khan E, Chang H et al. Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but Not del17p13 in multiple myeloma: Results of the Canadian MM016 trial. Blood 2007; 110: (Abstract 3597).
19. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21: 529-534.
20. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al Superiority of thalidomide and dexamethasone over vincristinedoxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
21. Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group. Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
22. Fermand J-P, Jaccard A, Macro M, Uzunhan Y, Allard C, Castaigne S et al. A randomized comparison of dexamethasone+thalidomide (Dex/Thal) vs Dex+Placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). Blood 2006; 108: (Abstract 3563).
23. Macro M, Divine M, Uzunhan Y, Jaccard A, Bouscary D, Leblond V et al Dexamethasone+thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): A randomized trial. Blood 2006; 108: (Abstract 57).
24. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L et al. Multicenter, randomized, double-blind, placebocontrolled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26: 2171-2177.
25. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
26. Morgan G, Davies FE, Owen RG, Rawstron AC, Bell S, Cocks K et al. Thalidomide combinations improve response rates; results from the MRC IX study. Blood 2007; 110: (Abstract 3593).
27. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al. Prevention of thalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
28. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/ Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
29. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B et al Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179-1184.
30. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. A randomized phase III trial of lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Blood 2006; 108: (Abstract 799).
31. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S et al BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008; 111: 1101-1109.
32. Harousseau J, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 2006; 91: 1498-1505.
33. Rosinol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25: 4452-4458.
34. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Mohty MMM et al. VELCADE/Dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): Updated results of the IFM 2005/01 trial. Blood 2007; 110: (Abstract 450).
35. Cavo M, Patriarca F, Tacchetti P, Galli M, Perrone G, Petrucci MT et al. Bortezomib (VELCADE)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood 2007; 110: (Abstract 73a).
36. Palumbo A, Avonto I, Patriarca F, Crippa C, Petrucci MT, Rossini F et al. Bortezomib, pegylated-liposomal-doxorubicin and dexamethasone followed by melphalan 100mg/m2 in elderly newly diagnosed patients: An interim analysis. Blood 2007; 110: (Abstract 448a).
37. Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Avigan D et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): Preliminary results of a phase 1/2 study. Blood 2007; 110: (Abstract 187).
38. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
39. Spencer A, Prince M, Roberts AW, Bradstock KF, Prosse IW. First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6). Blood 2006; 108: (Abstract 58a).
40. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood 2008; 111: 1805-1810.
41. Schillera GJ, Liaoa M, Sohna JP, Malonea R, Bartonia K, Habtemariam B et al. Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma. Biol Blood Marrow Transplant 2008; 14 (2 Suppl 1): (Abstract 176).
42. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: Results of a randomized controlled trial. Blood 2004; 104: 3052-3057.
43. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007; 370: 1209-1218.
44. Ludwig H, Tothova E, Hajek R, Drach J, Labar B, Egyed M et al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: Second interim analysis. Haematologica 2007; 92 (S1): (Abstract 446a).
45. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367 825-831.
46. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C et al Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 2007; 110: (Abstract 75a).
47. Waage A, Gimsing P, Juliusson G, Turesson I, Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: A placebo controlled randomized phase 3 trial. Blood 2007; 110: (Abstract 78a).
48. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, Prednisone, and Lenalidomide Treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007; 25: 4459-4465.
49. Mateos MV, Hernandez JM, Hernandez MT, Gutiérrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase I/II study. Blood 2006; 108: 2165-2172.
50. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
51. Terpos E, Dimopoulos MA, Sezer O. The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875-1884.
52. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334-338.
53. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025-2034.